Status:
COMPLETED
Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
Lead Sponsor:
Bronx Psychiatric Center
Collaborating Sponsors:
Pfizer
Buffalo Psychiatric Center
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Because ziprasidone has not been extensively studied and is not widely accepted in the severely mentally ill in State hospitals this study aims to demonstrate its effectiveness and relative lack of si...
Detailed Description
Ziprasidone has been found in studies and practice to be efficacious and tolerated well but has not been well studied or well accepted in the very severely ill in State Hospitals. This study aims to f...
Eligibility Criteria
Inclusion
- Schizophrenia or schizoaffective
- Capacity to give consent
- Stable, on the same medication for a month but only partial response or with unacceptable side effects 18-65 years of age
Exclusion
- Repeated non-compliance
- Current depot medication
- Active medical conditions
- QTc \>500msec
- Previous non-response
- Previous treatment with ziprasidone
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00458211
Start Date
May 1 2005
End Date
April 1 2008
Last Update
May 1 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Buffalo Psychiatric Center
Buffalo, New York, United States, 14213
2
Bronx Psychiatric Center
The Bronx, New York, United States, 10461